Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $26 on Ariad Pharmaceuticals on Tempered Iclusig Outlook

Related ARIA
JMP Securities Downgrades Ariad, Cites Limited Near-Term Upside In Light Of Prescription Trends
The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind
Bernie Sanders's Destruction Of Ariad (Seeking Alpha)

Stifel Nicolaus maintained Ariad Pharmaceuticals (NASDAQ: ARIA) with a Buy rating and lowered the price target from $27.00 to $26.00.

Stifel Nicolaus noted, "We surveyed 34 hematology/oncology specialists in February. Results continue to suggest best-in-class potential for Iclusig in third-line and later-line therapy but greater uncertainty than before regarding Iclusig's front-line potential on the heels of black box warnings for thrombosis and hepatotoxicity. We decrease our target price to $26 from $27 as we decrease our Iclusig sales and out-year EPS estimates."

Ariad Pharmaceuticals closed at $20.08 on Wednesday.

Latest Ratings for ARIA

Oct 2016JMP SecuritiesDowngradesMarket OutperformMarket Perform
Oct 2016JP MorganDowngradesNeutralUnderweight
Oct 2016SunTrust Robinson HumphreyInitiates Coverage onBuy

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings


Related Articles (ARIA)

View Comments and Join the Discussion!